July 2, 2018 07:40 AM EDT
Financing

With $100M in fresh back­ing and a new TCR ini­tia­tive, Athenex launch­es Chi­na JV

John Carroll

Editor & Founder

A year af­ter John­son Lau out­lined the full mea­sure of his plans for a biotech come­back in an S-1 fil­ing for Athenex $AT­NX, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Beam shares promis­ing first clin­i­cal da­ta on gene edit­ing treat­ment for a lung and liv­er dis­ease 

Ex­clu­sive: FDA blocks drug and de­vice re­view­ers from tak­ing HH­S' buy­out of­fer

New Flag­ship start­up aims to trail­blaze ‘AI sci­ence fac­to­ries’

Tre­vi’s mid-stage chron­ic cough da­ta meet ‘home run’ sce­nario, stock soars

J&J, Pro­tag­o­nist out­line first IBD win for oral IL-23 with $5B+ sales po­ten­tial

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times